JPRN-UMIN000049478已完成Unknown
Immune Response to SARS-CoV-2 Vaccine in Multiple Sclerosis Patients on Disease-Modifying Drugs - Immune Response to SARS-CoV-2 Vaccine in Multiple Sclerosis Patients on Disease-Modifying Drugs
Osaka University Department of Neurology, Osaka University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2022年11月11日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Has been infected with SARS-CoV-2 virus up to 3 months after the second mRNA vaccination against SARS-CoV-2. Known allergy or contraindication to any vaccine component. Has received treatment with another vaccine within 4 weeks of the first SARS-CoV-2 mRNA vaccine. Participating in another clinical trial. Has used steroids within 3 months of the first SARS-CoV-2 mRNA vaccine and within 3 months of the second dose. Received intravenous or subcutaneous immunoglobulin (IVIG/SCIG) within 3 months after the first or second dose of SARS-CoV-2 mRNA vaccine. Other cases in which the attending physician deems it inappropriate.
研究者
相似试验
进行中（未招募）
1 期
Response to corona vaccination in patients with primary Sjögren's syndromePrimary Sjögren's syndromeEUCTR2021-001414-10-NLniversity Medical Center Groningen180
已完成
4 期
Vaccine response against SARS-CoV-2 in patients with primary Sjögren*s syndrome1000381610047438Sjögren's syndromeNL-OMON51179niversitair Medisch Centrum Groningen180
已完成
不适用
Immune response against SARS-CoV-2 vaccinatioCOVID-19DRKS00028174DKFZ6
尚未招募
不适用
Can vaccination produce protective antibodies in people who fail to develop protective antibodies after recovery from COVID-19 infectioCTRI/2021/04/032572Rajiv Gandhi Cancer Institute and Research Centre
进行中（未招募）
1 期
Immune response to COVID-19 Vaccination in people with Diabetes MellitusType 1 Diabetes MellitusType 2 Diabetes MellitusEUCTR2021-001459-15-ATMedical University of Graz161